Dignitana newsletter highlights efficiencies, reimbursement, and growth

Files for download
Dignitana Release - wkr0006.pdf

Dignitana today publishes the investor newsletter recapping the company's work to improve efficiencies, advance reimbursement, and maintain strategic growth. The newsletter features recent media coverage of DigniCap, new locations, and answers to Frequently Asked Questions about reimbursement the US.

To read the December newsletter click here.

To receive future Dignitana news directly to your email, subscribe here.

For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com